
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5166414/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC. Case Reports in Oncology, 2022, 14, 1323-1327.	0.7	4
2	TDP1 and TOP1 as targets in anticancer treatment of NSCLC: Activity and protein level in normal and tumor tissue from 150 NSCLC patients correlated to clinical data. Lung Cancer, 2022, 164, 23-32.	2.0	2
3	Clinical features affecting efficacy of immune checkpoint inhibitors in pretreated patients with advanced NSCLC: a Danish nationwide real-world study. Acta Oncológica, 2022, 61, 409-416.	1.8	11
4	The impact of a tailored follow-up intervention on comprehensive geriatric assessment in older patients with cancer - a randomised controlled trial. Journal of Geriatric Oncology, 2021, 12, 41-48.	1.0	15
5	Co-occurring MET Amplification Predicts Inferior Clinical Response to First-Line Erlotinib in Advanced Stage EGFR-Mutated NSCLC Patients. Clinical Lung Cancer, 2021, 22, e870-e877.	2.6	6
6	Protein expression of programmed cell death ligand 1 and ligand 2 and their prognostic values in extensive-stage small cell lung cancer Journal of Clinical Oncology, 2021, 39, e20593-e20593.	1.6	0
7	<i>EGFR</i> transcription in nonâ€smallâ€cell lung cancer tumours can be revealed in ctDNA by cellâ€free chromatin immunoprecipitation (cfChIP). Molecular Oncology, 2021, 15, 2868-2876.	4.6	7
8	Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLC—Real World Efficacy. Cancers, 2021, 13, 4846.	3.7	19
9	cGAS-STING pathway expression as a prognostic tool in NSCLC. Translational Lung Cancer Research, 2021, 10, 340-354.	2.8	18
10	Surveillance With PET/CT and Liquid Biopsies of Stage I-III Lung Cancer Patients After Completion of Definitive Therapy: A Randomized Controlled Trial (SUPER). Clinical Lung Cancer, 2020, 21, e61-e64.	2.6	7
11	Clearing of circulating tumour DNA predicts clinical response to first line tyrosine kinase inhibitors in advanced epidermal growth factor receptor mutated non-small cell lung cancer. Lung Cancer, 2020, 141, 37-43.	2.0	24
12	Neurofilament Light Chain as A Biomarker for Brain Metastases. Cancers, 2020, 12, 2852.	3.7	20
13	Cell-free Chromatin Immunoprecipitation (cfChIP) from blood plasma can determine gene-expression in tumors from non-small-cell lung cancer patients. Lung Cancer, 2020, 147, 244-251.	2.0	12
14	Clearing of circulating tumour DNA predicts clinical response to osimertinib in EGFR mutated lung cancer patients. Lung Cancer, 2020, 143, 67-72.	2.0	17
15	Genomic Profiling of Circulating Tumor DNA Predicts Outcome and Demonstrates Tumor Evolution in ALK-Positive Non-Small Cell Lung Cancer Patients. Cancers, 2020, 12, 947.	3.7	20
16	Circulating miR-30b and miR-30c predict erlotinib response in EGFR-mutated non-small cell lung cancer patients. Lung Cancer, 2019, 135, 92-96.	2.0	22
17	Intraâ€individual variation of circulating tumour DNA in lung cancer patients. Molecular Oncology, 2019, 13, 2098-2106.	4.6	14
18	Impact of comprehensive geriatric assessment on short-term mortality in older patients with cancer—a follow-up study. European Journal of Cancer, 2019, 116, 27-34.	2.8	15

#	Article	IF	CITATIONS
19	A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project. Lung Cancer, 2019, 131, 95-103.	2.0	40
20	EGFR Gene Polymorphism Predicts Improved Outcome in Patients With EGFR Mutation-positive Non–small cell Lung Cancer Treated With Erlotinib. Clinical Lung Cancer, 2019, 20, 161-166.e1.	2.6	13
21	Up-Regulated FGFR1 Expression as a Mediator of Intrinsic TKI Resistance in EGFR-Mutated NSCLC. Translational Oncology, 2019, 12, 432-440.	3.7	20
22	The prognostic role of inflammation-scores on overall survival in lung cancer patients. Acta Oncológica, 2019, 58, 371-376.	1.8	15
23	Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project. Journal of Thoracic Oncology, 2018, 13, 413-425.	1.1	66
24	The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment. BMC Cancer, 2018, 18, 191.	2.6	14
25	Comorbidity in Lung Cancer: A Prospective Cohort Study of Self-Reported versus Register-Based Comorbidity. Journal of Thoracic Oncology, 2018, 13, 54-62.	1.1	21
26	A method for treatment monitoring using circulating tumour DNA in cancer patients without targetable mutations. Oncotarget, 2018, 9, 31066-31076.	1.8	18
27	Frailty status but not age predicts complications in elderly cancer patients: a follow-up study. Acta Oncológica, 2018, 57, 1458-1466.	1.8	27
28	<sup>18</sup> F-FDG PET/CT for Very Early Response Evaluation Predicts CT Response in Erlotinib-Treated Non–Small Cell Lung Cancer Patients: A Comparison of Assessment Methods. Journal of Nuclear Medicine, 2017, 58, 1931-1937.	5.0	16
29	Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non–Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified byÂVeriStrat Good versus VeriStrat Poor. The EuropeanÂThoracic Oncology Platform (ETOP) EMPHASIS-lung Trial. Journal of Thoracic Oncology, 2017, 12, 752-762.	1.1	17
30	Programmed Death Ligand 1 Expression in Paired Non–Small Cell Lung Cancer Tumor Samples. Clinical Lung Cancer, 2017, 18, e473-e479.	2.6	35
31	Correlation between circulating mutant DNA and metabolic tumour burden in advanced non-small cell lung cancer patients. British Journal of Cancer, 2017, 117, 704-709.	6.4	45
32	Dasatinib and Doxorubicin Treatment of Sarcoma Initiating Cells: A Possible New Treatment Strategy. Stem Cells International, 2016, 2016, 1-8.	2.5	12
33	Early Change in FDG-PET Signal and Plasma Cell-Free DNA Level Predicts Erlotinib Response in EGFR Wild-Type NSCLC Patients. Translational Oncology, 2016, 9, 505-511.	3.7	13
34	PD-L1 Expression and Survival among Patients with Advanced Non–Small Cell Lung Cancer Treated with Chemotherapy. Translational Oncology, 2016, 9, 64-69.	3.7	77
35	Ultra-micro samples can be used for mRNA quantification of lung cancer biomarkers. Scandinavian Journal of Clinical and Laboratory Investigation, 2016, 76, 243-248.	1.2	2
36	Metabolic tumor burden as marker of outcome in advanced EGFR wild-type NSCLC patients treated with erlotinib. Lung Cancer, 2016, 94, 81-87.	2.0	34

#	Article	IF	CITATIONS
37	Increase in soluble PD-1 is associated with prolonged survival in patients with advanced EGFR -mutated non-small cell lung cancer treated with erlotinib. Lung Cancer, 2016, 100, 77-84.	2.0	97
38	Exosomal Proteins as Diagnostic Biomarkers inÂLungÂCancer. Journal of Thoracic Oncology, 2016, 11, 1701-1710.	1.1	213
39	Gene Expression of the EGF System—a Prognostic Model in Non–Small Cell Lung Cancer Patients Without Activating EGFR Mutations. Translational Oncology, 2016, 9, 306-312.	3.7	7
40	The effect of direct access to CT scan in early lung cancer detection: an unblinded, cluster-randomised trial. BMC Cancer, 2015, 15, 934.	2.6	18
41	Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: An expert consensus. Lung Cancer, 2015, 87, 89-95.	2.0	40
42	Intravenous or oral administration of vinorelbine in adjuvant chemotherapy with cisplatin and vinorelbine for resected NSCLC. Lung Cancer, 2015, 88, 167-173.	2.0	13
43	2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. Annals of Oncology, 2015, 26, 1573-1588.	1.2	308
44	Genetic polymorphism in the epidermal growth factor receptor gene predicts outcome in advanced non-small cell lung cancer patients treated with erlotinib. Lung Cancer, 2015, 90, 314-320.	2.0	13
45	Randomized phase III trial of erlotinib vs. docetaxel in patients with advanced squamous cell non-small cell lung cancer (SqNSCLC) failing first line platinum based doublet chemotherapy stratified by VeriStrat Good vs VeriStrat Poor: The European Thoracic Oncology Platform (ETOP) EMPHASIS trial lournal of Clinical Oncology. 2015, 33, 8049-8049.	1.6	Ο
46	2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. Annals of Oncology, 2014, 25, 1475-1484.	1.2	210
47	Monitoring of epidermal growth factor receptor tyrosine kinase inhibitorâ€sensitizing and resistance mutations in the plasma DNA of patients with advanced non–small cell lung cancer during treatment with erlotinib. Cancer, 2014, 120, 3896-3901.	4.1	180
48	Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. Annals of Oncology, 2014, 25, 1681-1690.	1.2	246
49	Lungscape: Resected Non–Small-Cell Lung Cancer Outcome by Clinical and Pathological Parameters. Journal of Thoracic Oncology, 2014, 9, 1675-1684.	1.1	31
50	EGFR mutation frequency and effectiveness of erlotinib: A prospective observational study in Danish patients with non-small cell lung cancer. Lung Cancer, 2014, 83, 224-230.	2.0	41
51	2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. Annals of Oncology, 2014, 25, 1462-1474.	1.2	410
52	EGFR CA repeat polymorphism predict clinical outcome in EGFR mutation positive NSCLC patients treated with erlotinib. Lung Cancer, 2014, 85, 435-441.	2.0	11
53	Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays. BMC Cancer, 2014, 14, 294.	2.6	135
54	Intravenous or oral administration of vinorelbine in adjuvant chemotherapy with cisplatin and vinorelbine after surgery for NSCLC Journal of Clinical Oncology, 2014, 32, e18501-e18501.	1.6	0

#	Article	IF	CITATIONS
55	Surgery for NSCLC stages T1-3N2MO having preoperative pathologically verified N2 involvement: A prospective randomized multinational phase III trial by the Nordic Thoracic Oncology Group Journal of Clinical Oncology, 2013, 31, 7504-7504.	1.6	14
56	The European Thoracic Oncology Platform Lungscape project: Clinical outcome data as a basis for molecular correlations in resected non-small cell lung cancer Journal of Clinical Oncology, 2013, 31, 7514-7514.	1.6	2
57	Characterization of pulmonary lesions in patients with suspected lung cancer: computed tomography versus [18F]fluorodeoxyglucose-positron emission tomography/ computed tomography. Cancer Imaging, 2012, 12, 437-446.	2.8	8
58	Erlotinib Accumulation in Brain Metastases from Non-small Cell Lung Cancer: Visualization by Positron Emission Tomography in a Patient Harboring a Mutation in the Epidermal Growth Factor Receptor. Journal of Thoracic Oncology, 2011, 6, 1287-1289.	1.1	124
59	Complete Pathologic Response in Lung Tumors in Two Patients with Metastatic Non-small Cell Lung Cancer Treated with Erlotinib. Journal of Thoracic Oncology, 2011, 6, 1946-1949.	1.1	12
60	Long-term bladder, colorectal, and sexual functions after radical radiotherapy for urinary bladder cancer. Radiotherapy and Oncology, 2004, 72, 139-145.	0.6	63
61	A new quantitative RT–PCR assay for thymidylate synthase mRNA in blood leukocytes applied to cancer patients and healthy controls. Clinica Chimica Acta, 2000, 290, 129-144.	1.1	3
62	Loss of abh antigen expression in bladder cancer is not caused by loss of heterozygosity of the ABO locus. International Journal of Cancer, 1995, 63, 341-344.	5.1	11
63	Metronomic oral vinorelbine doublet chemotherapy with carboplatin in treatment of advanced lung cancer: a feasibility and safety study. F1000Research, 0, 10, 673.	1.6	0